Iovance Biotherapeutics, Inc.
0JDK.L
London Stock Exchange4.24
USD
+0.26
- -
Iovance Biotherapeutics, Inc.
0JDK.L
(London Stock Exchange)
Recent
price
4.24
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Iovance Biotherapeutics, Inc. is a commercial-stage biotechnology firm dedicated to developing and delivering innovative cancer immunotherapies that leverage a patient's own immune system to target and eliminate malignant cells. The company has advanced its proprietary tumor-infiltrating lymphocyte (TIL) technology, establishing a unique platform for personalized cellular treatments. Their lead therapeutic, Amtagvi (lifileucel), a tumor-derived autologous T cell immunotherapy, received accelerated approval from the U.S. Food and Drug Administration in February 2024 for adult patients with unresectable or metastatic melanoma who have previously undergone specific systemic treatments. Health Canada also granted conditional marketing authorization for Amtagvi in August 2025. Iovance's development pipeline includes ongoing clinical programs evaluating TIL cell therapies such as lifileucel in advanced melanoma, including a Phase 3 study for frontline advanced melanoma, and other solid tumors like non-small cell lung cancer and various gynecologic cancers. The company also markets Proleukin (aldesleukin), an interleukin-2 product utilized within the Amtagvi regimen. Iovance Biotherapeutics aims to be a leader in TIL therapy, pushing forward with continuous innovation, including next-generation genetically modified TILs. The company, which was founded in 2007 and rebranded from Lion Biotechnologies, Inc. in June 2017, maintains its headquarters in San Carlos, California.